TT
TTX.F Theralase Technologies Inc
- Market cap
- EUR 33.2M
- P/E
- -
- P/B
- 7.41x
- ROE
- -61.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is TTX.F undervalued?
Graham numberThe Graham number of Theralase Technologies Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Theralase Technologies Inc fundamental analysis
No fundamental analysis for Theralase Technologies Inc yet.
Theralase Technologies Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Theralase Technologies Inc
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer…
Full company profileTheralase Technologies Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Theralase Technologies Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.92M | 2.34M | 1.73M | 964K | 929K | 781K | 1.14M | 1.07M | 1.03M | 816K | 594K |
| Gross Profit | 1.12M | 1.40M | 948K | 60.8K | 270K | 310K | 628K | 562K | 554K | 507K | 300K |
| Operating Income | -4.91M | -6.08M | -3.37M | -7.42M | -5.70M | -4.54M | -5.23M | -4.59M | -4.29M | -4.18M | -4.19M |
| EBITDA | - | -5.84M | -3.13M | -7.15M | -5.32M | -4.13M | -4.90M | -4.25M | -3.96M | -3.81M | -3.91M |
| Net Income | -4.92M | -6.09M | -3.36M | -7.41M | -5.60M | -4.41M | -5.24M | -4.57M | -4.26M | -4.12M | -4.19M |
| EPS | - | -0.05 | -0.02 | -0.04 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 6.24M | 3.32M | 3.56M | 15.5M | 10.0M | 5.94M | 4.16M | 3.28M | 3.25M | 3.49M | 8.13M |
| Total Liabilities | 550K | 1.28M | 2.57M | 1.61M | 857K | 875K | 1.07M | 1.37M | 1.18M | 1.72M | 1.28M |
| Shareholders' Equity | 5.69M | 2.05M | 999K | 13.9M | 9.16M | 5.07M | 3.09M | 1.91M | 2.07M | 1.78M | 6.84M |
| Cash & Short-term Investments | 2.97M | 254K | 1.03M | 12.5M | 7.88M | 3.69M | 1.51M | 43.9K | 269K | 183K | 5.26M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.88M | -4.26M | -1.22M | -6.57M | -4.45M | -4.03M | -5.13M | -4.07M | -3.33M | -3.29M | -2.95M |
| Capital Expenditure | 296K | 410K | 134K | 533K | 165K | 101K | 70.4K | 37.3K | 20.0K | 48.9K | 10.9K |
| Free Cash Flow | - | -4.67M | -1.35M | -7.10M | -4.61M | -4.13M | -5.20M | -4.11M | -3.35M | -3.33M | -2.96M |
| Ratios | |||||||||||
| ROE | -86.5% | -297.9% | -336.1% | -53.5% | -61.1% | -87.0% | -169.3% | -239.9% | -205.9% | -231.8% | -61.2% |
| ROA | -78.9% | -183.4% | -94.2% | -47.9% | -55.9% | -74.2% | -125.8% | -139.5% | -131.1% | -117.9% | -51.5% |
| Net Profit Margin | -256.5% | -260.1% | -193.6% | -769.0% | -602.6% | -565.1% | -459.8% | -427.1% | -411.8% | -504.7% | -705.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Theralase Technologies Inc dividends
Theralase Technologies Inc has not paid dividends in the last 9 fiscal years.
Who owns Theralase Technologies Inc
- Insiders 8.45%
- Institutions 0.00%
- Public & others 91.55%
- Shares outstanding 310M
- Free float 291M
Theralase Technologies Inc company profile
- Company name
- Theralase Technologies Inc
- Ticker
- TTX.F
- ISIN
- CA88337V1004
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- 41 Hollinger Road, Toronto, ON, Canada, M4B 3G4
- Phone
- 416 699 5273
- Website
- theralase.com
About Theralase Technologies Inc
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of energy activated small molecules and associated drug formulations in Canada, the United States, and internationally. The company operates in two segments, Drug Division and Device Division. It engages in the research and development of Rutherrin, an injectable form of Ruvidar for the treatment of glio blastoma multiforme, a form of brain cancer, non-small cell lung cancer, pancreatic cancer, colorectal cancer, and muscle invasive bladder cancer; and Ruvidar, a topical treatment for herpes simplex virus-1 lesions and an extracorporeal treatment for lymphoma, leukemia, and multiple myeloma. The company also researches, develops, manufactures, and distributes Cool Laser Therapy systems to healthcare practitioners for the healing of pain. Theralase Technologies Inc. is based in Toronto, Canada.
Theralase Technologies Inc management
5- Mr. Roger John Dumoulin-White B.Sc., P.Eng.President, CEO & Chairman
- Ms. Kristina Hachey CPACFO & Director
- Dr. Arkady Mandel DSc., M.D., Ph.D.Chief Scientific Officer & Director
- Mr. David M. Groves B.APresident of World Trade Division
- Dr. Terry Ruch DVMEquine Medical Consultant